Ireland-headquartered Jazz Pharmaceuticals (Nasdaq: JAZZ) and UK biotech Redx Pharma (AIM: REDX) today announced a definitive agreement under which Jazz will acquire Redx's KRAS (Kirsten rat sarcoma virus) inhibitor program.
Jazz and Redx, whose shares rocketed a massive 45% to 29.00 pence by midday, will collaborate to advance candidates through investigational new drug (IND) enabling studies; Jazz will be responsible for all clinical development, regulatory, manufacturing and commercialization activities.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze